Breaks Categories: News

MondaySep 30, 2024 1:35 pm

NetworkNewsBreaks – DoubleDown Interactive Co. Ltd. (NASDAQ: DDI) Extends Partnership with American Cancer Society to Support ‘Impactful Work’

DoubleDown Interactive (NASDAQ: DDI), a leading developer and publisher of digital games on mobile and web-based platforms, today announced plans to donate $10,000 to the American Cancer Society during Breast Cancer Awareness Month. According to the announcement, DoubleDown Casino will host the Penny’s Stride for the Cure play-to-enter giveaway on October 5-6, 2024. The event will offer players the opportunity to engage with and show support for the charitable donation and learn more about the importance of the organization’s annual Making Strides Against Breast Cancer walks. “DoubleDown Interactive is proud to partner with the American Cancer Society for the fourth…

Continue Reading

MondaySep 30, 2024 1:22 pm

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients. “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” said Annovis…

Continue Reading

MondaySep 30, 2024 11:40 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting…

Continue Reading

MondaySep 30, 2024 11:40 am

NetworkNewsBreaks – WAGMI Miami, LIF3.com Partner for Upcoming 2025 Conference

WAGMI Miami, the flagship event for blockchain and Web3 innovators, today announced LIF3.com, a complete, omni-channel DeFi ecosystem and a leader in decentralized finance, as a Platinum Sponsor for the upcoming conference scheduled for January 21-24, 2025. The partnership is expected to play a crucial role in helping support the advancement of decentralized finance’s future through innovation and collaboration. The announcement noted that with LIFE.com now onboard as a sponsor, the 2025 WAGMI Miami event is poised to be the most impactful and exciting edition yet. “Partnering with LIF3.com is a milestone for WAGMI Miami,” commented Moe Levin, Founder of…

Continue Reading

MondaySep 30, 2024 10:51 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop

Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics. “We were honored to be invited to participate in the Long…

Continue Reading

MondaySep 30, 2024 10:29 am

NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets (after depreciation), and total current liabilities of approximately $1.36 million as of June 30, 2024. During fiscal 2024, the company utilized net cash of approximately $6.31 million for operating activities, including certain expenditures for Phase 1a/1b clinical trial of NV-387 and drug manufacturing costs for…

Continue Reading

FridaySep 27, 2024 3:33 pm

NetworkNewsBreaks – Key Trump Media & Technology Group Corp. (NASDAQ: DJT) Investor Unloads 11M Shares

United Atlantic Ventures LLC (“UAV”), a key investor in Trump Media & Technology Group (NASDAQ: DJT), significantly reduced its stake by selling nearly 11 million shares, leaving it with a mere 100 shares. This move came after a federal judge’s approval and the end of a lock-up period that initially restricted insiders from selling their shares. UAV, co-founded by Andrew Litinsky and Wes Moss, who played a pivotal role in conceptualizing a social media venture with Donald Trump, found itself embroiled in legal battles with Trump Media concerning their shareholdings. Despite these disputes and the fluctuating fortunes of Trump Media’s…

Continue Reading

FridaySep 27, 2024 3:20 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Continue Reading

FridaySep 27, 2024 3:08 pm

NetworkNewsBreaks – Blockchain Futurist Conference Series Records Biggest Year Yet, Reports Acquisition by Emerald

The 6th Annual Blockchain Futurist Conference, Canada’s largest and most high-profile Web3, blockchain and cryptocurrency event, was held in mid-August at the Revel Entertainment Complex and Cabana Pool Bar in Toronto. A recap of the event noted that this was by far the biggest year ever for the event series. More than 8,000 people attended, while 250+ distinguished speakers, 130+ media, 80+ community partners, 15+ sub-events at the venue, and more than 75 sub-events across Toronto as part of Canada Crypto Week helped make the event a success. The event featured numerous engaging events and activations throughout. In addition, during…

Continue Reading

FridaySep 27, 2024 2:37 pm

NetworkNewsBreaks – Upstream Stands Out as the First Direct Access Stock Market Built on Blockchain Technology

Upstream, a MERJ Exchange market and trading app, today hosted the latest episode of “Upstream Up Close” on Twitter (X) Spaces. In a blog post discussing the episode, Upstream’s Anastasia Samaras stated that while other traditional exchanges have begun exploring blockchain solutions, they have used more cautious approaches. Samaras listed several factors that may hinder the full-scale adoption of blockchain technology, including regulation, complexity, and disruption. For its part, Upstream is the only stock market built on blockchain technology offering investors direct access to U.S. and international equities. The post noted that the success of Upstream as a blockchain-powered stock…

Continue Reading